Sanofi S.R.O. (Czech Republic)

Sanofi-Aventis S.R.O. is a pharmaceutical company located in Prague, Czech Republic. The company has been operating since 1992 and offers a range of products and services. Their portfolio includes innovative drugs from Sanofi, over-the-counter medications, vaccines from Sanofi Pasteur, and medications for rare diseases from Sanofi Genzyme. Sanofi's logo can be found on every fifth medication used by Czech patients, and they manufacture half of the top-selling drugs, including popular ones like Paralen and Ibalgin. The company focuses on finding new, more effective, affordable, and patient-friendly treatment methods. They invest approximately five billion euros annually in research and development, with plans to increase this amount to six billion euros by 2020. Currently, their research teams are working on 50 projects and vaccines in clinical development, with the potential to introduce 15 new products to the market in the coming years. Sanofi offers highly innovative products, particularly for the treatment of diabetes, oncological diseases, cardiology, transplantation, and hemodialysis. They also provide a wide range of medications for the central nervous system, including epilepsy, insomnia, and schizophrenia treatments. Additionally, Sanofi's product portfolio includes medications for internal medicine, such as osteoporosis and rheumatoid arthritis, urological issues, antimalarials, pain relief, common cold, allergies, and more. The company's main goals include developing cutting-edge medications for the prevention and treatment of cardiovascular diseases. They currently have medications on the market for hypertension, heart failure, and products that reduce the risk of cardiovascular events, such as heart attacks, strokes, and cardiovascular death. Sanofi is also recognized for its advancements in the treatment of various types of cancer, particularly colorectal and breast cancer, as well as complications associated with chemotherapy in children with leukemia.